Wealth Enhancement Advisory Services LLC Boosts Holdings in Humana Inc. (NYSE:HUM)

Wealth Enhancement Advisory Services LLC boosted its stake in Humana Inc. (NYSE:HUM) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,848 shares of the insurance provider’s stock after acquiring an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Humana were worth $2,245,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HUM. State Street Corp lifted its holdings in shares of Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after purchasing an additional 53,272 shares during the last quarter. FMR LLC boosted its holdings in shares of Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Pzena Investment Management LLC grew its position in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after acquiring an additional 187,903 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Humana by 118.9% in the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after acquiring an additional 774,085 shares during the period. Finally, Legal & General Group Plc raised its position in Humana by 2.1% in the 2nd quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 1.7 %

NYSE HUM opened at $282.57 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $455.53. The business has a 50 day moving average price of $274.33 and a two-hundred day moving average price of $309.10. The stock has a market cap of $34.02 billion, a PE ratio of 25.03, a P/E/G ratio of 2.12 and a beta of 0.55.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, sell-side analysts predict that Humana Inc. will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. Humana’s dividend payout ratio (DPR) is 31.36%.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HUM shares. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. UBS Group decreased their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Barclays increased their price target on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and a consensus price target of $302.00.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.